CN111593073A - 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 - Google Patents
双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 Download PDFInfo
- Publication number
- CN111593073A CN111593073A CN202010191574.7A CN202010191574A CN111593073A CN 111593073 A CN111593073 A CN 111593073A CN 202010191574 A CN202010191574 A CN 202010191574A CN 111593073 A CN111593073 A CN 111593073A
- Authority
- CN
- China
- Prior art keywords
- gene
- reporter gene
- plasmid
- pseudovirus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 79
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 68
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 61
- 241001112090 Pseudovirus Species 0.000 title claims abstract description 59
- 239000013598 vector Substances 0.000 title claims abstract description 34
- 206010035664 Pneumonia Diseases 0.000 title description 4
- 241001573881 Corolla Species 0.000 title description 2
- 241000700605 Viruses Species 0.000 claims abstract description 35
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 34
- 241000711573 Coronaviridae Species 0.000 claims abstract description 30
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 20
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 17
- 101710188315 Protein X Proteins 0.000 claims abstract description 17
- 108060001084 Luciferase Proteins 0.000 claims abstract description 15
- 239000005089 Luciferase Substances 0.000 claims abstract description 15
- 108091006047 fluorescent proteins Proteins 0.000 claims abstract description 12
- 102000034287 fluorescent proteins Human genes 0.000 claims abstract description 12
- 108700004030 rev Genes Proteins 0.000 claims abstract description 5
- 101150098213 rev gene Proteins 0.000 claims abstract description 5
- 101150047047 gag-pol gene Proteins 0.000 claims abstract description 3
- 239000005090 green fluorescent protein Substances 0.000 claims description 16
- 102100021696 Syncytin-1 Human genes 0.000 claims description 15
- 229940096437 Protein S Drugs 0.000 claims description 13
- 230000009977 dual effect Effects 0.000 claims description 13
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 12
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 12
- 101710198474 Spike protein Proteins 0.000 claims description 12
- 102000029301 Protein S Human genes 0.000 claims description 9
- 108090000331 Firefly luciferases Proteins 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 241000710831 Flavivirus Species 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 241000711950 Filoviridae Species 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 2
- 101710177509 Major immediate early protein Proteins 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000713112 Orthobunyavirus Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 108010052090 Renilla Luciferases Proteins 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 108091081024 Start codon Proteins 0.000 claims description 2
- 241000907316 Zika virus Species 0.000 claims description 2
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 2
- 230000003494 hepatotrophic effect Effects 0.000 claims description 2
- 230000001553 hepatotropic effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 108010054624 red fluorescent protein Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 102220097517 rs876659265 Human genes 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 3
- 229960005486 vaccine Drugs 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000001976 enzyme digestion Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 101100203795 Severe acute respiratory syndrome coronavirus 2 S gene Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 2
- 101000898310 Homo sapiens Enhancer of filamentation 1 Proteins 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 240000000220 Panda oleosa Species 0.000 description 2
- 235000016496 Panda oleosa Nutrition 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 101100545229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ZDS2 gene Proteins 0.000 description 1
- 101100113084 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs2 gene Proteins 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101100167209 Ustilago maydis (strain 521 / FGSC 9021) CHS8 gene Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
- C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010191574.7A CN111593073B (zh) | 2020-03-18 | 2020-03-18 | 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010191574.7A CN111593073B (zh) | 2020-03-18 | 2020-03-18 | 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111593073A true CN111593073A (zh) | 2020-08-28 |
CN111593073B CN111593073B (zh) | 2022-03-08 |
Family
ID=72187255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010191574.7A Active CN111593073B (zh) | 2020-03-18 | 2020-03-18 | 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111593073B (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111926041A (zh) * | 2020-10-16 | 2020-11-13 | 广州吉妮欧生物科技有限公司 | 一种SARS-CoV-2假病毒小鼠体内包装系统及其制备方法 |
CN112301043A (zh) * | 2020-10-13 | 2021-02-02 | 中国医学科学院病原生物学研究所 | 一种新型冠状病毒SARS-CoV-2复制子、其构建方法及应用 |
CN112592923A (zh) * | 2020-12-11 | 2021-04-02 | 中国科学院深圳先进技术研究院 | Ires序列、ires序列的应用和多顺反子表达载体 |
CN112746059A (zh) * | 2020-09-15 | 2021-05-04 | 清华大学 | 基于病毒结构蛋白遗传互补的冠状病毒细胞模型 |
CN113073113A (zh) * | 2021-04-06 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 一种监测新冠病毒刺突蛋白S1特异性CTLs功能的可视化小鼠模型的构建方法及应用 |
CN113156113A (zh) * | 2021-01-27 | 2021-07-23 | 中日友好医院(中日友好临床医学研究所) | 用于体外评价新型冠状病毒ade效应的系统及其构建方法 |
CN113444745A (zh) * | 2021-05-25 | 2021-09-28 | 安徽省立医院(中国科学技术大学附属第一医院) | 病毒s蛋白突变体假病毒盘的构建及其疫苗评价应用 |
CN113817802A (zh) * | 2021-08-26 | 2021-12-21 | 首都医科大学附属北京地坛医院 | 新冠病毒包膜蛋白突变体侵入能力非诊断评价方法 |
WO2021254341A1 (zh) * | 2020-06-16 | 2021-12-23 | 睿丰康生物医药科技(浙江)有限公司 | 一种冠状病毒假病毒包装系统及其包装方法、冠状病毒假病毒在评估消杀效力中的应用 |
CN113930437A (zh) * | 2020-06-29 | 2022-01-14 | 四川大学华西医院 | 一种病毒报告基因及其在抗SARS-CoV-2药物筛选中的用途 |
CN114134175A (zh) * | 2021-11-01 | 2022-03-04 | 中国医学科学院输血研究所 | 一种同时表达RFP和luciferase的SARS-CoV-2假病毒系统的包装和检测方法 |
CN114231544A (zh) * | 2020-09-09 | 2022-03-25 | 复旦大学 | 基于细菌人工染色体的新冠病毒SARS-CoV-2亚基因组复制子克隆、构建及应用 |
WO2022120819A1 (zh) * | 2020-12-11 | 2022-06-16 | 中国科学院深圳先进技术研究院 | Ires序列、ires序列的应用和多顺反子表达载体 |
CN114657213A (zh) * | 2022-05-23 | 2022-06-24 | 华南农业大学 | 一种猪急性腹泻综合征冠状病毒人工染色体重组载体及其构建方法和应用 |
CN114913920A (zh) * | 2022-07-19 | 2022-08-16 | 中科南京生命健康高等研究院 | 双报告基因假病毒检测系统的建立与应用 |
WO2024067770A1 (zh) * | 2022-09-28 | 2024-04-04 | 云舟生物科技(广州)股份有限公司 | 一种慢病毒包装试剂盒 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552851A (zh) * | 2003-06-06 | 2004-12-08 | 北京大学 | Sars冠状病毒的假病毒及其制备方法和用途 |
CN102083462A (zh) * | 2007-08-03 | 2011-06-01 | 巴斯德研究院 | 慢病毒基因转移载体及其医学应用 |
CN104830908A (zh) * | 2015-06-02 | 2015-08-12 | 中国食品药品检定研究院 | 假病毒包装系统及其用途 |
CN105602991A (zh) * | 2015-12-31 | 2016-05-25 | 四川农业大学 | 一种乙脑假病毒及其制备方法 |
CN106754757A (zh) * | 2016-12-23 | 2017-05-31 | 中国疾病预防控制中心病毒病预防控制所 | 高滴度双报告基因的可视化模拟病毒及其应用 |
-
2020
- 2020-03-18 CN CN202010191574.7A patent/CN111593073B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552851A (zh) * | 2003-06-06 | 2004-12-08 | 北京大学 | Sars冠状病毒的假病毒及其制备方法和用途 |
CN102083462A (zh) * | 2007-08-03 | 2011-06-01 | 巴斯德研究院 | 慢病毒基因转移载体及其医学应用 |
CN104830908A (zh) * | 2015-06-02 | 2015-08-12 | 中国食品药品检定研究院 | 假病毒包装系统及其用途 |
CN105602991A (zh) * | 2015-12-31 | 2016-05-25 | 四川农业大学 | 一种乙脑假病毒及其制备方法 |
CN106754757A (zh) * | 2016-12-23 | 2017-05-31 | 中国疾病预防控制中心病毒病预防控制所 | 高滴度双报告基因的可视化模拟病毒及其应用 |
Non-Patent Citations (10)
Title |
---|
SCOTT R. WITTING ET AL.: "Characterization of a 3rd Generation Lentiviral Vector Pseudotyped With Nipah Virus Envelope Proteins For Endothelial Cell Transduction", 《GENE THER.》 * |
孙克宁等: "慢病毒载体的构建及其应用于转基因动物的研究进展", 《中国畜牧兽医》 * |
张昕等: "表达萤光素酶的HIV药物筛选细胞模型的建立", 《生物技术通讯》 * |
张蕊等: "慢病毒载体的研究进展及应用", 《中国畜牧兽医》 * |
樊全荣等: "携带Fluc和ZsGreen双报告基因小鼠", 《中国癌症杂质》 * |
王国富: "基因治疗中病毒载体的研究进展", 《大理学院学报》 * |
王旭娜等: "假病毒技术在医学中的应用研究进展", 《健康之路》 * |
管洁等: "含分泌型萤光素酶和绿色荧光蛋白双报告基因的慢病毒载体的制备与表达分析", 《生物技术通讯》 * |
阮峥等: "第三代慢病毒包装系统优化及 Rev表达质粒对慢病毒包装效率作用初探", 《生物技术通讯》 * |
黄睿等: "假病毒在丙型肝炎病毒研究中的应用", 《军事医学科学院院刊》 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021254341A1 (zh) * | 2020-06-16 | 2021-12-23 | 睿丰康生物医药科技(浙江)有限公司 | 一种冠状病毒假病毒包装系统及其包装方法、冠状病毒假病毒在评估消杀效力中的应用 |
CN113930437A (zh) * | 2020-06-29 | 2022-01-14 | 四川大学华西医院 | 一种病毒报告基因及其在抗SARS-CoV-2药物筛选中的用途 |
CN114231544A (zh) * | 2020-09-09 | 2022-03-25 | 复旦大学 | 基于细菌人工染色体的新冠病毒SARS-CoV-2亚基因组复制子克隆、构建及应用 |
CN112746059A (zh) * | 2020-09-15 | 2021-05-04 | 清华大学 | 基于病毒结构蛋白遗传互补的冠状病毒细胞模型 |
CN112301043A (zh) * | 2020-10-13 | 2021-02-02 | 中国医学科学院病原生物学研究所 | 一种新型冠状病毒SARS-CoV-2复制子、其构建方法及应用 |
CN111926041A (zh) * | 2020-10-16 | 2020-11-13 | 广州吉妮欧生物科技有限公司 | 一种SARS-CoV-2假病毒小鼠体内包装系统及其制备方法 |
CN111926041B (zh) * | 2020-10-16 | 2020-12-25 | 广州吉妮欧生物科技有限公司 | 一种SARS-CoV-2假病毒小鼠体内包装系统及其制备方法 |
WO2022120819A1 (zh) * | 2020-12-11 | 2022-06-16 | 中国科学院深圳先进技术研究院 | Ires序列、ires序列的应用和多顺反子表达载体 |
CN112592923A (zh) * | 2020-12-11 | 2021-04-02 | 中国科学院深圳先进技术研究院 | Ires序列、ires序列的应用和多顺反子表达载体 |
CN113156113A (zh) * | 2021-01-27 | 2021-07-23 | 中日友好医院(中日友好临床医学研究所) | 用于体外评价新型冠状病毒ade效应的系统及其构建方法 |
CN113073113A (zh) * | 2021-04-06 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 一种监测新冠病毒刺突蛋白S1特异性CTLs功能的可视化小鼠模型的构建方法及应用 |
CN113444745A (zh) * | 2021-05-25 | 2021-09-28 | 安徽省立医院(中国科学技术大学附属第一医院) | 病毒s蛋白突变体假病毒盘的构建及其疫苗评价应用 |
CN113817802A (zh) * | 2021-08-26 | 2021-12-21 | 首都医科大学附属北京地坛医院 | 新冠病毒包膜蛋白突变体侵入能力非诊断评价方法 |
CN114134175A (zh) * | 2021-11-01 | 2022-03-04 | 中国医学科学院输血研究所 | 一种同时表达RFP和luciferase的SARS-CoV-2假病毒系统的包装和检测方法 |
CN114657213A (zh) * | 2022-05-23 | 2022-06-24 | 华南农业大学 | 一种猪急性腹泻综合征冠状病毒人工染色体重组载体及其构建方法和应用 |
CN114657213B (zh) * | 2022-05-23 | 2022-08-02 | 华南农业大学 | 一种猪急性腹泻综合征冠状病毒人工染色体重组载体及其构建方法和应用 |
CN114913920A (zh) * | 2022-07-19 | 2022-08-16 | 中科南京生命健康高等研究院 | 双报告基因假病毒检测系统的建立与应用 |
CN114913920B (zh) * | 2022-07-19 | 2022-12-27 | 中科南京生命健康高等研究院 | 双报告基因假病毒检测系统的建立与应用 |
WO2024067770A1 (zh) * | 2022-09-28 | 2024-04-04 | 云舟生物科技(广州)股份有限公司 | 一种慢病毒包装试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN111593073B (zh) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111593073B (zh) | 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 | |
AU2018229561B2 (en) | Recombinant adenoviruses and use thereof | |
US11667890B2 (en) | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion | |
CN111295449B (zh) | 腺病毒载体及其用途 | |
US6361972B1 (en) | Compositions and methods for non-targeted activation of endogenous genes | |
US20030119104A1 (en) | Chromosome-based platforms | |
ES2805045T3 (es) | Vectores lentivirales | |
ES2388527T3 (es) | Vacunas de VIH basadas en Env de múltiples clados de VIH | |
KR20220125332A (ko) | Pcsk9의 표적화를 위한 조성물 및 방법 | |
KR102516697B1 (ko) | 조작된 캐스케이드 구성성분 및 캐스케이드 복합체 | |
WO2004067743A1 (en) | Vaccine production using transposon based vectors | |
US11129890B1 (en) | Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein | |
PT1984512T (pt) | Sistema de expressão génica utilizando excisão-união em insetos | |
WO2008151633A2 (en) | Vectors for vaccines against lentivirus infections | |
CN111094569A (zh) | 光控性病毒蛋白质、其基因及包含该基因的病毒载体 | |
CN113692225B (zh) | 经基因组编辑的鸟类 | |
DK3063278T3 (en) | PREPARATION OF VIRAL VECTORS | |
KR20240037192A (ko) | 게놈 통합을 위한 방법 및 조성물 | |
US6740503B1 (en) | Compositions and methods for non-targeted activation of endogenous genes | |
CA2522166C (en) | Lambda integrase mutein for use in recombination | |
RU2774631C1 (ru) | Сконструированные компоненты cascade и комплексы cascade | |
CN110819657B (zh) | 一种减毒棒状病毒的制备方法及应用 | |
KR20240029020A (ko) | Dna 변형을 위한 crispr-트랜스포손 시스템 | |
KR20230153437A (ko) | 코로나바이러스를 방지하는 백신 생산을 위한 완전 합성 장쇄 핵산 | |
CN115768470A (zh) | 用于疫苗生产以防范冠状病毒的全合成的长链核酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200828 Address after: 311200 4th floor, building 2, ChuanHua Kechuang building, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Applicant after: Huijun biomedical technology (Hangzhou) Co.,Ltd. Address before: Second, 150 teaching building, No. 215000 benevolence Road, Suzhou Industrial Park, Suzhou, Jiangsu Applicant before: SUZHOU ULTRAIMMUNE Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201123 Address after: Office 1201-1, innovation building, 1000 Linjiang East Road, bailongqiao Town, Wucheng District, Jinhua City, Zhejiang Province 321000 Applicant after: Ruifengkang biomedical technology (Zhejiang) Co.,Ltd. Address before: 311200 4th floor, building 2, ChuanHua Kechuang building, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Applicant before: Huijun biomedical technology (Hangzhou) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Double reporter gene skeleton vector, four plasmid pseudovirus packaging system, packaging COVID-19 pseudovirus Effective date of registration: 20221220 Granted publication date: 20220308 Pledgee: Bank of Jinhua Limited by Share Ltd. Wucheng branch Pledgor: Ruifengkang biomedical technology (Zhejiang) Co.,Ltd. Registration number: Y2022980028346 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231221 Granted publication date: 20220308 Pledgee: Bank of Jinhua Limited by Share Ltd. Wucheng branch Pledgor: Ruifengkang biomedical technology (Zhejiang) Co.,Ltd. Registration number: Y2022980028346 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Double reporter gene skeleton vector, four plasmid pseudovirus packaging system, packaging COVID-19 pseudovirus Granted publication date: 20220308 Pledgee: Bank of Jinhua Limited by Share Ltd. Wucheng branch Pledgor: Ruifengkang biomedical technology (Zhejiang) Co.,Ltd. Registration number: Y2024980002578 |